A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Not Yet Recruiting
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: East-West Medical Research Institute, Honolulu, Hawaii
Conditions: Hypertension
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Not Yet Recruiting
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: East-West Medical Research Institute, Honolulu, Hawaii
Conditions: Hypertension
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Not Yet Recruiting
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: East-West Medical Research Institute, Honolulu, Hawaii
Conditions: Hypertension, Overweight or Obesity
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Active Not Recruiting
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: East-West Medical Research Institute, Honolulu, Hawaii
Conditions: Obesity, Overweight, Overweight or Obesity
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Active Not Recruiting
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Pacific Diabetes & Endocrine Center, Honolulu, Hawaii
Conditions: Obesity, Overweight, Type 2 Diabetes